

Figure S1. Effect of Gem and IL-8 on the proliferation of Gem-S PaCa cell lines. Gem-S MIA PaCa-2 cells were treated with Gem at the indicated concentrations and with or without IL-8 for 72 h, after which the proliferation of each cell line was evaluated using WST-1 assays. Values are expressed as means \pm SD. Multiple group comparisons were performed by one-way analysis of variance (ANOVA) with a post hoc Bonferroni test. NS, not significant. MIA PaCa-2 (S) + IL-8, Gem-S MIA PaCa-2 cells treated with IL-8; MIA PaCa-2 (S) IL-8: Gem-S MIA PaCa-2 cells not treated with IL-8. Gem, gemcitabine; PaCa, pancreatic cancer; Gem-S, gemcitabine sensitive; IL-8, interleukin-8.




Figure S2. Effect of Gem treatment and siRNA-mediated IL-8 knockdown on the proliferation of Gem-R PaCa cell lines. (A) IL-8 mRNA expression in Gem-R PaCa cell lines (MIA PaCa-2) transfected with IL-8 siRNA or negative control siRNA. Expression levels were measured by RT-qPCR and normalized to GAPDH expression levels. Gem-R MIA PaCa-2 siNC, Gem-R MIA PaCa-2 cells transfected with negative control siRNA; Gem-R MIA PaCa-2 siIL-8, Gem-R MIA PaCa-2 cells transfected with IL-8 siRNA. Values are expressed as means \pm SD. Differences in means were determined by unpaired t-tests. * $P < 0.01$. (B) Gem-R MIA PaCa-2 cells transfected with IL-8 siRNA or negative control siRNA were treated with Gem at the indicated concentrations for 72 h, and the proliferation of each cell line was determined using WST-1 assays. MIA PaCa-2 (R) siIL-8, Gem-R MIA PaCa-2 cells transfected with IL-8 siRNA; MIA PaCa-2 (R) siNC, Gem-R MIA PaCa-2 cells transfected with negative control siRNA. Values are expressed as means \pm SD. Multiple group comparisons were performed by one-way analysis of variance (ANOVA) with a post hoc Bonferroni test. NS, not significant. Gem, gemcitabine; PaCa, pancreatic cancer; Gem-R, gemcitabine resistant; IL-8, interleukin-8.

